Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 701–800 of 1,000
High MICB expression as a biomarker for good prognosis of colorectal cancer
Feng, Q., Yu, S., Mao, Y., Ji, M., Wei, Y., He, G., Chang, W., Zhu, D., Ren, L., & Xu, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03159-0 · Cited by 18
“2009), and associated with rejection to tumors in transplanted mice model (Diefenbach et al. 2001).”
BackgroundSavid-Frontera, C., Viano, M. E., Baez, N. S., Lidon, N. L., Fontaine, Q., Young, H. A., Vimeux, L., Donnadieu, E., & Rodriguez‐Galán, M. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971001 · Cited by 16
“The Ag-independent mechanisms achieved by bystander CD8+ T cells might rely on NKG2D-ligands recognition (10, 11), granzyme/perforin release (15, 16) and high IFNg production (3, 12–14).”
BackgroundInfluentialHackl, H., Stocker, G., Charoentong, P., Mlecnik, B., Bindea, G., Galon, J., & Trajanoski, Z. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.012 · Cited by 17
“…of the NK and CD8+ T cells with various tumor cell lines using a system of differential equations (De Pillis & Radunskaya, 2003) and proposed new forms for the tumorimmune competition terms, and validate these forms through comparison with the experimental data (Diefenbach et al., 2001).”
BackgroundDAP10 Deficiency Breaks the Immune Tolerance against Transplantable Syngeneic Melanoma
Hyka‐Nouspikel, N., Lucian, L., Murphy, E. A., McClanahan, T., & Phillips, J. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3763 · Cited by 16
MICA-129Met/Val Polymorphism Is Associated with Early-Onset Breast Cancer Risk
Ouni, N., Chaaben, A. B., Kablouti, G., Lajnef, M., Ayari, F., Abaza, H., Damak, T., Harzallah, L., Benammar-Elgaaeid, A., Guémira, F., et al. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1336175 · Cited by 15
“Such engagement activates antitumor effects of Natural killer (NK) cells and co-simulates γδCD8 T cells to mount adequate immune response (Diefenbach et al., 2001; Jinushi et al., 2003).”
BackgroundHuman NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment
Orrantia, A., Terrén, I., Astarloa-Pando, G., Zenarruzabeitia, O., & Borrego, F. (2021) · Cancers · doi:10.3390/cancers13071589 · Cited by 17
Mou, X., Zhou, Y., Jiang, P., Zhou, T., Jiang, Q., Xu, C., Liu, H., Zheng, T., Yuan, G., Zhang, Y., et al. (2014) · Scientific Reports · doi:10.1038/srep06138 · Cited by 19
Pascal, V., Brunet, C., Pradel, V., Thirion, X., André, P., Faucher, C., Sampol, J., Dignat‐George, F., Blaise, D., Vivier, É., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402670 · Cited by 17
MHC and MHC‐related proteins as pleiotropic signal molecules
Ojcius, D. M., Delarbre, C., Kourilsky, P., & Gachelin, G. (2002) · The FASEB Journal · doi:10.1096/fj.01-0758com · Cited by 15
A sense of tumour for the immune system
Todryk, S. M. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01506.x · Cited by 15
Cho, M. M., Song, L., Quamine, A. E., Szewc, F., Shi, L., Ebben, J. D., Turicek, D. P., Kline, J. M., Burpee, D. M., Lafeber, E. O., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008755 · Cited by 14
Towards the use of cybernetics for an enhanced cervical cancer care strategy
Nsugbe, E. (2022) · Intelligent Medicine · doi:10.1016/j.imed.2022.02.001 · Cited by 14
miR-aculous new avenues for cancer immunotherapy
Tang, W. W., Bauer, K. M., Barba, C., Ekiz, H. A., & O’Connell, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929677 · Cited by 15
Poggi, A. D., Zancolli, M., Boero, S., Catellani, S., Musso, A., & Zocchi, M. R. (2010) · International Journal of Cancer · doi:10.1002/ijc.25682 · Cited by 14
Zhang, W., Wang, F., Hu, X., Liang, J., Liu, B., Guan, Q., & Liu, S. (2018) · Oncology Letters · doi:10.3892/ol.2018.9720 · Cited by 15
Duan, X., Mao, X., & Sun, W. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1272 · Cited by 14
Model‐free feedback design for a mixed cancer therapy
Chareyron, S., & Alamir, M. (2009) · Biotechnology Progress · doi:10.1002/btpr.114 · Cited by 14
“The model recalled and described below is however based on published statements derived from clinical validations [ 8 ,9,22] as well as on reasonable assumptions depicted on Table 1. It is worth recalling however that the model is not used in the derivation of the control law, but only in the validation step.”
MethodPrinz, D., Klein, K., List, J., Knab, V. M., Menzl, I., Leidenfrost, N., Heller, G., Polić, B., Putz, E. M., Witalisz‐Siepracka, A., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.201948222 · Cited by 15
Innate Tumor Immune Surveillance
Smyth, M. J., Swann, J. B., & Hayakawa, Y. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-34814-8_7 · Cited by 14
Roshani, R., Ghafourian, M., Talaiezadeh, A., & Khodadadi, A. (2015) · Tumor Biology · doi:10.1007/s13277-015-4584-7 · Cited by 13
“(MICA), leading to induction of immune response against tumor cells [16, 17].”
BackgroundInnate lymphoid cells and cancer at border surfaces with the environment
Mattiola, I., & Diefenbach, A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.06.001 · Cited by 13
Self-citationShi, Y., Pan, J., Hang, C., Tan, L. A., Li, H., Yan, Z., & Zhu, J. (2023) · Environmental Toxicology · doi:10.1002/tox.23791 · Cited by 13
“A lot of activating receptors, excepting for FcγRIIIa, were enriched in NK cells, among which NKG2D is participating in tumor immunosurveillance and cell rejection.(57,58) Furthermore, NK cells could also react to effector molecules by releasing cytokines (i.”
BackgroundRetractedKotturi, H. S. R., Li, J., Branham-O’Connor, M., Stickel, S. L., Yu, X., Wagner, T. E., & Wei, Y. (2008) · Gene Therapy · doi:10.1038/gt.2008.77 · Cited by 16
Inflammatory Cytokine–Mediated Evasion of Virus-Induced Tumors from NK Cell Control
Mishra, R., Polić, B., Welsh, R. M., & Szomolanyi‐Tsuda, E. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203328 · Cited by 14
“Expression of NKG2D ligands on tumors transplanted into mice made them susceptible to rejection by NK cells in vivo (21, 22).”
BackgroundInnate lymphoid cells in early tumor development
Warner, K., Ghaedi, M., Chung, D. C., Jacquelot, N., & Ohashi, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948358 · Cited by 14
“Ectopic expression of NKG2D ligands in tumor cell lines results in tumor cell rejection in mice (151, 152).”
BackgroundReinforcement learning based control of tumor growth with chemotherapy
Hassani, A., & Sistani, M. B. N. (2010) · International Conference on System Science and Engineering · doi:10.1109/icsse.2010.5551776 · Cited by 13
Functional Specialization of Dendritic Cell Subsets
Heidkamp, G. F., Lehmann, C. H. K., Heger, L., Baransk, A., Hoffmann, A., Lühr, J. J., & Dudziak, D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30076-1 · Cited by 16
Natural killer cells in cancer
Höglund, P., & Klein, E. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.08.002 · Cited by 13
Luo, Y., Lu, J., Lei, Z., Zhu, H., Rao, D., Wang, T., Fu, C., Zhang, Z., Xia, L., & Huang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00621-w · Cited by 13
“The NKG2D receptor is important for the antitumor immune role of NK cells [228, 229].”
BackgroundWang, C., Wu, L., Li, X., Mao, S., Wang, Z., Xie, H., Xu, J., Li, D., Yang, H., Wang, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009621 · Cited by 13
Mathematical Modeling and Analysis of Tumor Growth Models Integrating Treatment Therapy
Kamran, M., Abdullah, J. Y., Satmi, A. S. A., Genisa, M., Majeed, A., & Nadeem, T. (2025) · Mathematical and Computational Applications · doi:10.3390/mca30060119 · Cited by 12
“The tumor growth has been impacted by the interactions of natural killer cells represented by − a 3 τ ℵ , cytotoxic cells − β 1 τ Ł, and therapy − b τ τ C ( t ) [36,39].”
Changes in natural killer cell subsets in pediatric liver transplant recipients
Pham, B., Piard, K., Silva, R., Gallo, A. E., Esquivel, C. O., Martinez, O. M., & Krams, S. M. (2012) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2012.01653.x · Cited by 12
Best Practices in Mathematical Modeling
de Pillis, L. G., & Radunskaya, A. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-050-2_4 · Cited by 12
Destruction of solid tumors by immune cells
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2016) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2016.08.020 · Cited by 12
Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy
Niu, Y.-X., Xu, Z., Yu, L., Lu, Y., Wang, Y., Wu, C., Hou, Y.-B., Li, J., Huang, S., Song, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108783 · Cited by 12
Savithri, B., & Khar, A. (2005) · European Journal of Immunology · doi:10.1002/eji.200535350 · Cited by 13
López, Á. G., Seoane, J. M., & Sanjuán, M. A. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157689 · Cited by 12
“Among these works, a mathematical model was validated using experiments frommice [16] and men [17].”
MethodLin, F., Dai, C., Ge, X., Tang, W., Lin, Y., Wang, Y., & Li, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.104 · Cited by 12
MicroRNA-34a promotes MICB expression in hepatocytes
Zhou, M., Zhao, C., Chen, X., Zhang, H., Li, G., Lou, H., Huang, W., Wei, L.-J., Li, D., Wu, X., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy128 · Cited by 12
Teng, M. W. L., Kershaw, M. H., Hayakawa, Y., Cerruti, L., Jane, S. M., Darcy, P. K., & Smyth, M. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505331200 · Cited by 12
Labarthe, M., Halanek, N., Birchall, L., Russell, N., Desel, C., Todryk, S. M., Peters, M., Lucas, A., Falkenberg, F. W., Dalgleish, A. G., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0061-2 · Cited by 12
“An important caveat, however, is that although important, anti-murine melanoma immunity does not rely exclusively on CTL responses; CD4+ T cell, macrophages and humoral responses have also been shown to play a role [6, 20, 21, 33, 45].”
BackgroundKhalili, P., & Vatankhah, R. (2023) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2023.111437 · Cited by 11
Cell-cell interactions mediating primary and metastatic breast cancer dormancy
Lenart, N. A., & Rao, S. S. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10223-5 · Cited by 11
Selvan, S. R., & Dowling, J. P. (2015) · BioMed Research International · doi:10.1155/2015/869547 · Cited by 12
“‘‘Adherent’’ versus Other Isolation Strategies for”
Wang, J., Li, C. R., Yang, D., Jian, X., & Jiang, C. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.2.715 · Cited by 11
Cheng, M., Zhi, K., Gao, X., He, B., Li, Y.-C., Han, J., Zhang, Z., & Wu, Y. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-166 · Cited by 11
“Thus NK and CD8 +T cells are capable of removing cancer cells that highly express NKG2D ligands [10].”
BackgroundLysenko, O., Schulte, D., Mittelbronn, M. G. A., & Steinle, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065345 · Cited by 13
Optimal control of mixed immunotherapy and chemotherapy of tumours with discrete delay
Krishnapriya, P., & Pitchaimani, M. (2015) · International Journal of Dynamics and Control · doi:10.1007/s40435-015-0221-y · Cited by 11
“showed that the model simulations have been validated by comparing the outcome both to mouse and human data [56,57].”
ResultLee, G. H., An, H. J., Kim, T. H., Kim, G., Park, K., Park, H., Lee, T. H., & Kwon, A. (2021) · Yonsei Medical Journal · doi:10.3349/ymj.2021.62.4.288 · Cited by 11
“Contemporary studies have revealed the importance of NKG2D function in host-mediated tumor immunity.(17,18) Many studies have demonstrated that in various human tumor microenvironments, NKG2D receptor expression is significantly lower on immune cells such as NK cells and CD8 T cells, thereby allowing tumor cells to es…”
BackgroundKohlhapp, F. J., O’Sullivan, J. A., Moore, T. V., Zloza, A., & Guevara-Patino, J. A. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2022.12.013 · Cited by 11
Suzuki, D., Tsuji, K., Yamamoto, T., Fujii, K., & Iwatsuki, K. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.06.005 · Cited by 11
“The C-type lectin-like receptor NKG2D, which does not associate with CD94, unlike other NKG2 family members, plays a key role in innate and adaptive immune responses in activating receptors [21,22].”
BackgroundA MATHEMATICAL MODEL OF IMMUNE RESPONSE TO TUMOR INVASION INCORPORATED WITH DANGER MODEL
Li, X., & Xu, J. (2015) · Journal of Biological Systems · doi:10.1142/s0218339015500266 · Cited by 11
Wu, P. (2005) · Frontiers in bioscience · doi:10.2741/1770 · Cited by 12
“mobilization of Ca2+ (32), production of cytokines such as IFN-gamma? (29, 30, 32-34), GM-CSF (31, 34), TNF-alpha? (33), TNF-beta ?(31)? ?as well as chemokines like macrophage inflammatory protein-1 (MIP-1) (33,34).”
BackgroundDasgupta, A., Shields, J. E., & Spencer, H. T. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.172 · Cited by 12
“In mouse models, the expression of NK-stimulatory NKG2D ligands induces not only short-term rejection of tumors but also a protective adaptive immune response (Diefenbach et al., 2001).”
BackgroundMechanisms of the self/non-self-survey in the defense against cancer: Potential for chemoprevention?
Sharma, R. A., & Browning, M. J. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.12.009 · Cited by 15
Prevalence of the NKG2D Thr72Ala Polymorphism in Patients with Cervical Carcinoma
Roszak, A., Lianeri, M., & Jagodziński, P. P. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0308 · Cited by 11
Therapy strategy in tumour cells and immune system interaction mathematical model
Rozova, V. S., & Bratus, A. S. (2016) · Applicable Analysis · doi:10.1080/00036811.2016.1153630 · Cited by 11
“[27] describing the results of murine experiments.”
Wei, H. (2018) · Journal of Biological Dynamics · doi:10.1080/17513758.2017.1418028 · Cited by 11
“The function D in Equation (7) depends on the relative populations L/T because the experimental data in [19] show that per cent lysis appears to be a function of the ratio of CD8+T cells to tumour cells [16].”
BackgroundImmunotherapy of colorectal cancer
Smith, C. S., Dulphy, N., Salio, M., & Cerundolo, V. (2002) · British Medical Bulletin · doi:10.1093/bmb/64.1.181 · Cited by 12
Jeong, M., Cortopassi, F., See, J., Torre, C. D. L., Cerwenka, A., & Stojanovic, A. (2024) · European Journal of Immunology · doi:10.1002/eji.202250342 · Cited by 11
“CD16 or Ly49H [80], which might explain the reduced IFN-γ production when atRA-exposed NK cells were triggered via these receptors, or with tumor cells previously reported to express their cognate ligands [81-83].”
BackgroundImmunological strategies to target HIV persistence
Martrus, G., & Altfeld, M. A. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000289 · Cited by 10
“NK cell group 2D (NKG2D), an activating NK cell receptor belonging to the family of C-type lectin-like receptors [79,80] was shown to strongly activate NK cells following the binding to its ligands (NKG2D-Ls) [81].”
BackgroundViral escape from NK‐cell‐mediated immunosurveillance: A lesson for cancer immunotherapy?
Momayyezi, P., Bilev, E., Ljunggren, H., & Hammer, Q. (2023) · European Journal of Immunology · doi:10.1002/eji.202350465 · Cited by 10
“Besides its relevance in restraining viral infections, NKG2D also plays a crucial role in NK-cell-dependent tumor rejection [56, 57].”
BackgroundHigh Expression of MICA in Human Kidney Cancer Tissue and Renal Cell Carcinoma Lines
Jia, H., Liu, J., Zhou, C., Kong, F., Yuan, M., Sun, W., Wang, J., Liu, L., Zhao, J., & Luan, Y. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.4.1715 · Cited by 10
Flanagan, M. L., Khawli, L. A., Hu, P., & Epstein, A. L. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199194.90222.1a · Cited by 10
“Tumor cells engineered to express H60 were rejected in studies conducted by other laboratories.(5,37) In the present study, we sought to demonstrate whether delivery of the extracellular portion of H60 to experimental tumors could result in antitumor effects.”
BackgroundIn vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity
Nakata, J., Nakano, K., Okumura, A., Mizutani, Y., Kinoshita, H., Iwai, M., Hasegawa, K., Morimoto, S., Fujiki, F., Tatsumi, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.374 · Cited by 10
Song, H., Kim, Y., Park, G., Kim, Y.-S., Kim, S., Lee, H.-K., Chung, W. Y., Park, S. J., Han, S. Y., Cho, D.-H., et al. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2317 · Cited by 10
“Expression of NKG2D ligands can generally be induced in response to stress-associated signaling, including viral infection and malignant transformation (46,47).”
Biassoni, R., Ugolotti, E., & Maria, A. D. (2010) · Self/Nonself · doi:10.4161/self.1.2.11717 · Cited by 10
Comment on: A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
Gowal, S., de Giacomi, M., & Boudec, J. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0238 · Cited by 10
“Acquired” NKG2D Ligand Stimulates NK Cell–mediated Tumor Immunosurveillance
Wang, D., Gu, X., Liu, X., Liu, X., Wang, B., Lao, F., & Fang, M. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000276 · Cited by 9
Mathematical modeling of combined therapies for treating tumor drug resistance
Bao, K., Liang, G., Tian, T., & Zhang, X. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109170 · Cited by 9
Shen, Y., Wang, X., Jin, Y., Lu, J., Qiu, G.-M., & Wen, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2396 · Cited by 9
“…cell (either expressed as a result of the transformation process itself or induced by the ongoing but limited inflammatory response) are recognized by infiltrating lymphocytes such as natural killer T, natural killer or γδ T-cells, which are then stimulated to produce interferon-γ (IFN-γ) (24,26).”
Ruan, G., Wang, S., Zhu, L., Liao, X., Wang, X., Liao, C., Yan, L., Xie, H., Gong, Y., Gan, J., et al. (2021) · Aging · doi:10.18632/aging.202935 · Cited by 11
“Research on cancer models in vivo showed strongly that the activated immune receptor NKG2D participated in the anti-cancer immune response [24, 30, 31].”
BackgroundDevelopment of a murine model of lymph node metastases suitable for immunotoxicity studies
Egenolf, D., Rafferty, P., Brosnan, K., Walker, M., Jordan, J. L., Makropoulos, D., Kavalkovich, K. W., Watson, S., Johns, L., Volk, A. L., et al. (2010) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.12.001 · Cited by 9
Shatry, A. M., Roopenian, D. C., & Levy, R. B. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.12.440 · Cited by 9
McLaughlin, Q., Sojka, D. K., Kennedy, K. J., Piersma, S. J., & Sethakorn, N. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03503-7 · Cited by 8
“Some tumors evade recognition by NKG2D by cleavage of NKG2D-L, including MICA [129–131 IDO1, leading to increased ADAM10 expression and subsequent ADAM10-induced shedding of NKG2D ligands [122].”
The Metabolic Regulation of the NKG2D-Positive NK and T Cells and Their Role in Disease Progression
Tang, J., Lu, Y., Chen, M., Wu, Q., Li, Y., Qin, Y., Liang, S., Luo, S., & Liu, K. (2025) · Biomolecules · doi:10.3390/biom15111506 · Cited by 8
Aublin‐Gex, A., Jacolin, F., Diaz, O., Jacquemin, C., Marçais, A., Walzer, T., Lotteau, V., Vidalain, P., & Perrin‐Cocon, L. (2024) · European Journal of Immunology · doi:10.1002/eji.202350954 · Cited by 8
“NKG2D-dependent elimination of tumor cells has been documented in syngeneic mouse models of transplanted tumors [15].”
Tran, J. N. S. N., Mahmood, S., Carlyle, J. R., & Kung, S. K. P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.013 · Cited by 8
Xuan, X. Y., Zhang, J. F., Hu, G., Li, Q. R., Liu, P. P., & Du, Y. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.29 · Cited by 8
IL-18-dependent NKG2D ligand upregulation on accessory cells is mediated by the PI3K/GSK-3 pathway
Brandstadter, J. D., Chen, H., Jiang, S., Huang, X., & Yang, Y. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.2a0816-342r · Cited by 8
“Conversely, forced expression of NKG2D ligands on tumor cells can make otherwise refractory tumors sensitive to NK cellmediated killing [12].”
BackgroundRavindran, N. S., Sheriff, M. M., & Krishnapriya, P. (2017) · Journal of Biological Dynamics · doi:10.1080/17513758.2017.1381280 · Cited by 8
“13×10−10 [9,10] μ3 10 10 [15] p3 6×10−1 6×10−1 Estimated g4 1×105 1×105 [9] β 9×10−1 9×10−1 [5] a0 0.”
Kuang, X., Mo, D., Qin, Y., Ahir, B. K., Wang, J., Zhao, P., & Deng, Z. (2019) · Medicine · doi:10.1097/md.0000000000014767 · Cited by 8
“The MICA molecule is a ligand of the natural killing cell surface activating receptor, natural killing group 2 member D (NKG2D) molecule, which can effectively mediate natural killing cell killing of tumor cells by the binding activation of proteins.([7]) However, many membrane-positive MICA tumors release a solubleMI…”
BackgroundComparative proteomic analysis of insulin receptor isoform A and B signaling
Malaguarnera, R., Gabriele, C., Santamaria, G., Giuliano, M., Vella, V., Massimino, M., Vigneri, P. G., Cuda, G., Gaspari, M., & Belfiore, A. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111739 · Cited by 8
Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges
Oh, B. L. Z., Chan, L. W. Y., & Chai, L. Y. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1044946 · Cited by 8
Role of CD4 T lymphocytes in antitumor immunity
Rajnavölgyi, É., & Lányi, Á. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)87209-3 · Cited by 11
Potential Role of Natural Killer Cell Receptor-Expressing Cells in Immunotherapy for Leukemia
Tanaka, J., Asaka, M., & Imamura, M. (2005) · International Journal of Hematology · doi:10.1532/ijh97.04152 · Cited by 8
Role of CD4+ T lymphocytes in antitumor immunity
Rajnavölgyi, É., & Lányi, Á. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)87298-6 · Cited by 8
Correction: Cellular Expression, Trafficking, and Function of Two Isoforms of Human ULBP5/RAET1G
Eagle, R. A., Flack, G., Warford, A., Martínez-Borra, J., Jafferji, I., Traherne, J. A., Ohashi, M., Boyle, L. H., Barrow, A. D., Caillat‐Zucman, S., et al. (2009) · PLoS ONE · doi:10.1371/annotation/34238ee8-5128-4f1d-9ae2-6906c9764e49 · Cited by 8
Mixed Immunotherapy and Chemotherapy of Tumors: Optimal Control Approach
Zouhri, S., Saadi, S., Elmouki, I., Hamdache, A., Rachik, M., II-Mohammdia, U. H., & Othmane, S. (2013) · Cited by 7
Campos‐Silva, C., López-Borrego, S., Felgueres, M. J., Esteso, G., & Valés‐Gómez, M. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2022045263 · Cited by 8
Analysis of stochastic dynamics of tumor with drug interventions
Hussain, J., Bano, Z., Ahmed, W., & Shahid, S. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111932 · Cited by 7
Determining optimal combination regimens for patients with multiple myeloma
Aghaee, M., Ledzewicz, U., Robbins, M. D. H., Bezman, N., Cho, H. J., & Moore, H. A. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106492 · Cited by 8
“Label Description References a TC boosts N proliferation [28, 29, 30, 31, 32, 33] b N boosts TC proliferation [28, 34, 31] c TC increases activation/efficacy of N [29, 30, 31] d Shed antigens boost TC proliferation [35, 36, 37, 38, 39, 40] e N cells kill myeloma cells [41, 42, 43, 44, 45, 46] f TC cells kill myeloma c…”
BackgroundMathematical Modelling of Tumour Dormancy
Page, K. M. (2009) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/20094303 · Cited by 7
“Experimental data on mouse vaccine trials [84] showed that the vaccine increased c, the fractional tumour cell kill by the NK cells, d, the fractional tumour cell kill by the CD8+ T Cells, g, the maximal NK cell recruitment rate by the tumour and j, the maximum CD8+ T cell recruitment rate and decreased s, the steepne…”
BackgroundMathematical modeling of immune modulation by glucocorticoids
Yakimchuk, K. (2019) · Biosystems · doi:10.1016/j.biosystems.2019.104066 · Cited by 8
Wagner, A. K., Gehrmann, U., Hiltbrunner, S., Carannante, V., Luu, T. T., Näslund, T. I., Brauner, H., Kadri, N., Kärre, K., & Gabrielsson, S. (2021) · Cancers · doi:10.3390/cancers13020298 · Cited by 7
“The latter is exemplified by NKG2D, which binds to stress-induced ligands such as Rae-1γ and H60 in mice [16,17].”
BackgroundNF-κB p50/p65 Affects the Frequency of Ly49 Gene Expression by NK Cells
Pascal, V., Nathan, N. R., Claudio, E., Siebenlist, U. K., & Anderson, S. K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1751 · Cited by 10
Expression of H60 on Mice Heart Graft and Influence of Cyclosporine
Ye, Z., Feng, L., Huang, S., Li, S., He, Y., & Li, Y. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.06.096 · Cited by 7
Geldhof, A. B., Ginderachter, J. A. V., Liu, Y., Noël, W., & BAETSELIER, P. D. (2003) · Journal of Immunology Research · doi:10.1080/10446670310001626580 · Cited by 7
“The contribution of NK cells in the regulation of CTL activity has been documented in a number of experimental models, including xenospecific CTL generation (Smyth et al., 1998; Smyth and Kelly, 1999), induction of influenza virus-specific CTLs (Kos and Engleman, 1996) and priming of tumor-specific CTLs (Kurosawa et a…”
BackgroundInfluentialBifurcation analysis of tumor-immune dynamics under the dual Allee effects
Hernández–López, E., & Wang, X. (2025) · Mathematical Biosciences · doi:10.1016/j.mbs.2025.109483 · Cited by 6
Intratumoral T reg cell ablation elicits NK cell–mediated control of CD8 T cell–resistant tumors
Zhang, C., Chien, C., Jurgaitytė, E., Sakiyama, K., Bockman, A., Jo, Y., Lee, S., Silveria, S. L., Andrews, E., Mende, A., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adx4411 · Cited by 6
Self-citation
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.